Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux
About this trial
The investigators hypothesize that in patients with a new diagnosis of Pulmonary Interstitial Disease (PID), adding capillaroscopy to standard care increases the proportion of patients receiving a diagnosis of PID-Connective Tissue Disease (PID-CTD) within the first three months of follow-up, thereby reducing the time to diagnosis and facilitating the implementation of appropriate treatment as quickly as possible. Therefore, To confirm this hypothesis, it is necessary to know the characteristics of capillaroscopy in patients with a new diagnosis of PID.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female over 18 years of age;
Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist;
Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity measurement, immunological assessment including: screening for FAN, FR, and anti-CCP);
French-speaking patient with no comprehension difficulties;
Disqualifiers
Have previously undergone a capillaroscopy, regardless of the reason;
Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation;
Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic therapy;
Pregnant or breastfeeding women;
Trial design
Design model
Single group
Treatments tested in this trial
capillaroscopy
Diagnostic testCapillaroscopy will be performed during a specific consultation. During this examination, a device called a "video capillaroscope" is used to magnify and visualize the capillaries located at the base of the nail. The examination lasts approximately twenty minutes.
Treatment groups
48 Participants
are divided into 1 treatment groupGroup A: Diffuse interstitial lung diseases (DILD)Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Proportion of capillaroscopy abnormalities according to the classification proposed by the EULAR Study Group on Microcirculation in Rheumatic Diseases
Time frame
At baseline (Day 0)Secondary outcomes
1
Description of the criteria that may influence the results of capillary examination: proportion of smoking status categories (active smoker/non-smoker/former smoker) and number of cigarettes per day for active smokers
Time frame
At baseline (Day 0)2
Description of the criteria that may influence the results of capillary examination: number of cigarettes per day for active smokers
Time frame
At baseline (Day 0)3
Description of the criteria that may influence the results of capillary examination: proportion of patients who consume alcohol
Time frame
At baseline (Day 0)4
Description of the criteria that may influence the results of capillary examination: average number of standard drinks for active consumers.
Time frame
At baseline (Day 0)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov